Discover a recent study that has provided valuable insights into the experiences of Latine patients living with moderate to ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

Medically reviewed by Brendan Camp, MD Psoriasis affects about 3% of all adults in the United States, and Asian Americans have a lower-than-average risk for psoriasis. However, it's believed that ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

Published results showed “Latine” patients with psoriasis in the U.S. have unique experiences with their disease and ...

Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...

ALEXANDRIA, VA, UNITED STATES, February 4, 2025 /EINPresswire / -- The National Psoriasis Foundation (NPF) is pleased to announce an anonymous gift o ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...